Plasma Cluster of Differentiation 147 and Cognitive Impairment After Acute Ischemic Stroke.

BACKGROUND: Cluster of differentiation 147 (CD147) is a multifunctional transmembrane glycoprotein, but its effect on poststroke cognitive impairment (PSCI) is unclear. METHODS: The current study included 612 patients with ischemic stroke with plasma CD147 levels from a preplanned ancillary study of CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). Mini-Mental State Examination and Montreal Cognitive Assessment were used to evaluate cognitive function at the 3-month follow-up visit. PSCI was defined as a score of <27 for Mini-Mental State Examination or <25 for Montreal Cognitive Assessment. Logistic regression models and restricted cubic spline analyses were used to assess the associations between CD147 and PSCI. RESULTS: As defined by Mini-Mental State Examination, 317 participants developed PSCI. After multivariate adjustment, elevated plasma CD147 levels were significantly associated with higher odds of PSCI (odds ratio, 1.75 [95% CI, 1.21-2.51]). Multiple-adjusted spline regression model showed a linear association between plasma CD147 level and PSCI (P for linearity=0.038). Furthermore, adding plasma CD147 to conventional risk factors improved the discriminatory power (C statistics, 0.695 versus 0.711; P=0.047). Similar findings were observed when PSCI was defined by the Montreal Cognitive Assessment. CONCLUSIONS: Elevated plasma CD147 levels at admission were associated with higher odds of cognitive impairment at 3 months after stroke among patients with acute ischemic stroke, suggesting its potential role in the pathophysiological processes of PSCI. REGISTRATION: URL: https://clinicaltrials.gov/study/NCT01840072; Unique Identifier: NCT01840072.